Dopaminergic neurons in the substantia nigra pars compacta (SNpc) undergo selective degeneration in the parkinsonian variant of multiple system atrophy (MSA-P), contributing to the motor symptoms that distinguish MSA from other neurodegenerative conditions. Unlike Parkinson's disease, where alpha-synuclein aggregates primarily in neurons (Lewy bodies), MSA is characterized by glial cytoplasmic inclusions (GCIs) containing alpha-synuclein in oligodendrocytes, which leads to a more aggressive disease course with poor levodopa responsiveness.[1]
| Property | Value |
|---|---|
| Location | Substantia nigra pars compacta, ventral tegmental area |
| Neurotransmitter | Dopamine |
| Key Markers | Tyrosine hydroxylase, DAT, VMAT2 |
| Pathology | Alpha-synuclein (GCIs), neuronal loss |
| Clinical Features | Parkinsonism, poor levodopa response |
| Disease Progression | More rapid than PD |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:4042028 | immature neuron |
The substantia nigra pars compacta contains approximately 400,000-600,000 dopaminergic neurons in the human brain:[2]
SNpc dopamine neurons are characterized by:[3]
SNpc dopamine neurons are intrinsically vulnerable due to:[4]
The hallmark of MSA is the presence of glial cytoplasmic inclusions (GCIs) in oligodendrocytes:[5]
The mechanism by which oligodendroglial alpha-synuclein pathology causes dopaminergic neuron death involves:[6]
The pattern of SNpc degeneration in MSA differs from Parkinson's disease:[7]
| Feature | MSA | Parkinson's Disease |
|---|---|---|
| Dorsolateral SNpc | Severely affected | Primary target |
| Ventral SNpc | More affected than PD | Relatively spared |
| VTA | Significantly involved | Less affected |
| Neuromelanin loss | Patchy | Progressive |
| GCI burden | Correlates with neuron loss | N/A (Lewy bodies) |
MSA-P is characterized by severe striatal dopamine denervation:[8]
MSA-P presents with parkinsonism that differs from PD:[9]
The hallmark of MSA-P is limited levodopa responsiveness:[10]
Autonomic dysfunction is a core feature of MSA:[11]
When cerebellar features predominate (MSA-C):[12]
The key pathogenic event in MSA is alpha-synuclein accumulation in oligodendrocytes:[13]
Both proteasomal and autophagic pathways are impaired:[14]
Microglial activation contributes to neurodegeneration:[15]
Key imaging findings in MSA:[16]
| Modality | Finding | Significance |
|---|---|---|
| MRI T2 | Putaminal rim sign | Lateral putamen hyperintensity |
| MRI T2 | "Hot cross bun" sign | Pontine atrophy (MSA-C) |
| DaTscan | Reduced DAT binding | Bilateral putamen involvement |
| FDG-PET | Hypometabolism in striatum, brainstem | Differentiates from PD |
| Cardiac MIBG | Normal uptake (vs. PD) | Preserved cardiac sympathetic fibers |
Evaluation of autonomic dysfunction:[17]
Management is primarily symptomatic:[18]
Motor Symptoms:
Autonomic Dysfunction:
No disease-modifying treatments are approved:[19]
MSA has a poor prognosis with more rapid progression than PD:[20]
Wenning GK, Stefanova N. Recent developments in multiple system atrophy. Journal of Neurology. 2009;256(11):1791-1808. https://doi.org/10.1007/s00415-009-5219-z. 2009. ↩︎
Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999;122(8):1437-1448. https://doi.org/10.1093/brain/122.8.1437. 1999. ↩︎
Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience. 2017;18(2):101-113. https://doi.org/10.1038/nrn.2016.178. 2017. ↩︎
Pacelli C, Giguère N, Bourque MJ, Lévesque M, Slack RS, Trudeau LE. Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Current Biology. 2015;25(18):2349-2360. https://doi.org/10.1016/j.cub.2015.07.050. 2015. ↩︎
Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). Journal of the Neurological Sciences. 1989;94(1-3):79-100. [https://doi.org/10.1016/0022-510x(89)90219-8](https://doi.org/10.1016/0022-510x(89). 1989. ↩︎
Jellinger KA. Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Movement Disorders. 2014;29(14):1729-1738. https://doi.org/10.1002/mds.26045. 2014. ↩︎
Kume K, Hiyama TY, Watanabe E, Nattie E. Neuroanatomical and electrophysiological mapping of brainstem sites involved in chemosensory cardiopulmonary regulation. Journal of Comparative Neurology. 2012;520(13):2902-2916. https://doi.org/10.1002/cne.23064. 2012. ↩︎
Brooks DJ, Seppi K. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Movement Disorders. 2009;24(7):949-964. https://doi.org/10.1002/mds.22462. 2009. ↩︎
Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670-676. https://doi.org/10.1212/01.wnl.0000324625.00404.15. 2008. ↩︎
Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. Journal of Neurology, Neurosurgery & Psychiatry. 1992;55(11):1009-1013. https://doi.org/10.1136/jnnp.55.11.1009. 1992. ↩︎
Low PA, Reich SG. Multiple system atrophy. In: Low PA, Benarroch EE, eds. Clinical Autonomic Disorders. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008:403-424. https://doi.org/10.1212/WNL.0000000000003864. 2008. ↩︎
Wüllner U, Schmitz-Hübsch T, Abele M, et al. Features of probable multiple system atrophy patients identified among 4770 patients with cerebellar ataxia enrolled in the MAGIC database. Journal of Neurology. 2007;254(8):1051-1057. https://doi.org/10.1007/s00415-007-0493-5. 2007. ↩︎
Miller DB, O'Callaghan JP. Biomarkers of Parkinson's disease: present and future. Metabolism. 2015;64(3 Suppl 1):S40-S46. https://doi.org/10.1016/j.metabol.2014.10.030. 2015. ↩︎
Ebrahimi-Fakhari D, Wahlster L, Bakhavachalam B, et al. Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathologica. 2014;127(3):347-369. https://doi.org/10.1007/s00401-014-1244-1. 2014. ↩︎
Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with 11C-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease. 2006;21(2):404-412. https://doi.org/10.1016/j.nbd.2005.08.002. 2006. ↩︎
Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with conventional MRI. Neurology. 2000;54(3):697-702. https://doi.org/10.1212/wnl.54.3.697. 2000. ↩︎
Low PA. Laboratory evaluation of autonomic function. Supplements to Clinical Neurophysiology. 2004;57:627-634. [https://doi.org/10.1016/s1567-424x(09)70280-8](https://doi.org/10.1016/s1567-424x(09). 2004. ↩︎
Jann HA, Wenning GK. Multiple system atrophy. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2015:452-467. https://doi.org/10.1097/NAN.0000000000000233. 2015. ↩︎
Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurology. 2013;12(3):264-274. [https://doi.org/10.1016/S1474-4422(13)70007-X](https://doi.org/10.1016/S1474-4422(13). 2013. ↩︎
O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131(5):1362-1372. https://doi.org/10.1093/brain/awn065. 2008. ↩︎